Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus is a Norwood, Massachusetts drug developer testing cancer and obesity treatments that are not yet approved. It last closed at $3.01 on Nov 17, down 10.81% on the day. The average 12-month price target from 3 analysts is $27.67 (+819.2% from the last close), with a high of $33.00 and a low of $23.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in CRBP, 100% of them bullish and 0% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From CRBP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on CRBP in the past 90 days. The average target is $27.67, with a high of $33.00 and a low of $23.00, compared with the last close of $3.01.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 12 | Mizuho | Target lowered | Buy | $34 → $23 |
| Nov 11 | RBC Capital | Maintained | Buy | $33 |
| Nov 11 | Wedbush | Target lowered | Buy | $30 → $27 |
| Aug 7 | Oppenheimer | Target lowered | Buy | $52 → $48 |
| Aug 7 | HC Wainwright & Co. | Target lowered | Buy | $40 → $35 |
Technical Analysis
The stock is 25% below its 20 day and 78% below its 50 day average. It is 176% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 30), near oversold. The nearest support is the Pivot S1 at $2.86, and the nearest resistance the Pivot at $3.10.
| RSI (14) | 30.32 | Weak, oversold below 30 | Neutral |
| MACD | -0.60 | Above its signal line | Bullish |
| Stochastic | 29.1 | Middle of its range | Neutral |
| ADX (14) | 51.9 | Strong downtrend | |
| Williams %R | -87.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -123.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −22.2% | Change over 10 sessions | Bearish |
| ATR (14) | $0.45 | Typical daily range, 15.0% of price |
| RSI (14) | 27.20 | Oversold below 30 | Oversold |
| MACD | -1.65 | Below its signal line | Bearish |
| Stochastic | 3.9 | Near the bottom of its range | Oversold |
| ADX (14) | 29.0 | Trending down | |
| Williams %R | -97.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -118.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −62.9% | Change over 10 sessions | Bearish |
| ATR (14) | $1.25 | Typical daily range, 41.6% of price |
What happened before
See how CRBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CRBP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in CRBP in the last 90 days.
CRBP Institutional Ownership
Full report →- ▲68 buying vs 39 selling
- ▲Held by funds +19.0 pts
- ▲Funds holding +14
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 121 | 107 | +13.1% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 86.0% | 67.0% | +19.0 pts |
| New / increased | 26 / 42 | 23 / 29 | +30.8% |
| Reduced / sold out | 26 / 13 | 26 / 23 | −20.4% |
| Put/call ratio | 0.70 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRBP is in one of them and how their past CRBP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CRBP in an article yet. Here's the latest on the wider market.
About Corbus Pharmaceuticals Holdings
Corbus is a drug development company based in Norwood, Massachusetts, that is testing experimental medicines for cancer and obesity. Its cancer candidate, CRB-701, is an antibody drug conjugate designed to deliver a toxic payload to tumors that express a protein called Nectin-4. Its obesity candidate, CRB-913, is an oral pill that acts on the CB1 receptor and is designed to limit exposure in the brain. The company does not yet sell approved products, and it aims its treatments at people with solid tumors or obesity.
- Headquarters
- Norwood, MA



